Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05875987
Other study ID # HEMCS-044
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2023
Est. completion date May 10, 2024

Study information

Verified date May 2024
Source HemoSonics LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This pilot study will assess the performance of the Quantra System with the QStat Cartridge versus standard of care coagulation testing in bleeding pregnant women at delivery.


Description:

The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. The QStat Cartridge was developed to monitor hemostasis in patients that may experience a range of coagulopathies of various etiologies including fibrinolytic defects. These patients include the tobstetric hemorrhage population. The cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements performed in parallel yielding five parameters that depict the functional status of a patient's coagulation system. This single-center, prospective, observational pilot study will evaluate the performance of the Quantra System with the QStat Cartridge as compared to standard of care coagulation testing in bleeding pregnant women at delivery.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date May 10, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is > 18 years. - Subject is pregnant or at least 24 h postpartum - Subject is fluent in English language. - Subject is experiencing significant bleeding resulting in activation of the stage 2 OB hemorrhage protocol as defined by blood loss =1500ml at delivery or within the first 24 hours after delivery, and/or is hemodynamically unstable and/or is experiencing increased abnormal bleeding not responsive to OB stage 1 hemorrhage resuscitation. - Subject or subject's legally authorized representative (LAR) is willing to provide informed consent, either prospectively or by deferred consent. Exclusion Criteria: - Subject is incarcerated at the time of the study. - Subject is currently enrolled in a distinct study that might confound the results of the proposed study - Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks

Study Design


Intervention

Device:
Quantra System
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.

Locations

Country Name City State
United States Duke University Hospital Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
HemoSonics LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of Quantra Clot Time to laboratory aPTT test results Coagulation function assessed by Quantra Clot Time (CT, sec) and activated partial thromboplastin (aPTT, sec) test At the time the OB hemorrhage protocol is activated, anticipated with 24 hours after birth
Primary Comparison of Quantra Fibrinogen Contribution to Clot Stiffness to laboratory coagulation fibrinogen test results Coagulation function assessed by Quantra Fibrinogen Contribution to Clot Stiffness (FCS, hPa) and Clauss fibrinogen (mg/dL) test At the time the OB hemorrhage protocol is activated, anticipated with 24 hours after birth
Primary Comparison of Quantra Clot Time to ROTEM delta INTEM CT test results Coagulation function assessed by Quantra Clot Time (CT, sec) and ROTEM INTEM CT (sec) test At the time the OB hemorrhage protocol is activated, anticipated with 24 hours after birth
Primary Comparison of Quantra Fibrinogen Contribution to Clot Stiffness to ROTEM delta FIBTEM test results Coagulation function assessed by Quantra Fibrinogen Contribution to Clot Stiffness (FCS, hPa) and ROTEM FIBTEM (mm) test At the time the OB hemorrhage protocol is activated, anticipated with 24 hours after birth
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05379530 - TEG Use in Children Undergoing Procedures With High Anticipated Blood Loss N/A
Terminated NCT03085394 - Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery Phase 3
Withdrawn NCT04388722 - Monitoring Noninvasively for Infusion and Transfusion Optimization N/A
Completed NCT06365242 - Direct Oral Anticoagulants and Management of Blleding Following Dental Extractions. A Prospective Cohort Study.
Terminated NCT03186157 - Prevalence of Trephined Syndrome After Decompressive Craniectomy
Completed NCT03444792 - Mechanical Dilatation of the Cervix at Elective Caesarean Section to Reduce Post-Operative Blood Loss N/A
Recruiting NCT02733952 - Intravenous Tranexamic Acid Versus Pericervical Tourniquet To Decrease Blood Loss In Trans-Abdominal Myomectomy Phase 3
Recruiting NCT06399445 - Measurement of Blood Loss in Adenotonsillectomy During General Anesthesia According to the Application of Nondepolarizing Muscle Relaxants Phase 4